Key Takeaways
- Adam Rosenthal, CEO of Star Therapeutics, will present at the J.P. Morgan Healthcare Conference on January 12, 2026.
- The company’s lead program, VGA039, targets bleeding disorders, specifically von Willebrand disease (VWD).
- Interim data indicates significant bleed reductions in VWD patients undergoing treatment with VGA039.
Star Therapeutics Presents Leading Program at J.P. Morgan Conference
Star Therapeutics, a late clinical-stage biotechnology firm focused on developing innovative antibodies for bleeding disorders, announced that CEO Adam Rosenthal, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PT in San Francisco. The presentation will cover the company’s vision and progress, specifically highlighting its lead program, VGA039.
VGA039 is a pioneering monoclonal antibody therapy designed to address Protein S deficiencies, performing dual functions that promote platelet attachment and enhance fibrin deposition to restore hemostasis. This therapy has the potential to serve as a universal hemostatic treatment option for various bleeding disorders, with a primary focus on von Willebrand disease (VWD). Currently, VGA039 is in pivotal Phase 3 trials for VWD.
In December 2025, interim data from an ongoing Phase 1/2 multi-dose study were shared at the 67th American Society of Hematology (ASH) Annual Meeting. The results showcased a significant reduction in bleeds among all participating patients with different types of VWD, reflecting the promising efficacy of VGA039.
Star Therapeutics operates with a mission to explore and develop antibody therapies that address neglected biological areas and provide solutions for multiple diseases with singular therapies. The leadership team boasts extensive experience in antibody drug development, having previously created four first-in-class antibodies, including ENJAYMO®, the first approved treatment for cold agglutinin disease.
Based in South San Francisco, Star Therapeutics has successfully raised over $300 million from prominent life sciences investors, underscoring its potential in the biotechnology landscape. For further details, visit Star-Therapeutics.com and find Star Therapeutics on LinkedIn.
The content above is a summary. For more details, see the source article.